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Advances in the Diagnosis of Urothelial Neoplasia 
John D. Crissman, MD,* Richard J. Zarbo, MD,* Terri Johnson, MD,* 
V. Ramesh Babu, PhD,+ Fazlul H. Sarkar, PhD,* Brian J. Miles, MD,§ and 
Joseph C. Cerny, MD§ 
Urothelial neoplasia is a unique cancer in that it consists ofa spectrum of tumors with different 
biologic behaviors. The most common urothelial neoplasm is the low grade superficial papillary 
carcinoma or papilloma which may recur numerous times but does not result in significant morbidity 
or mortality. A variant ofthe superficial papillary carcinoma, which represents approximately 10% of 
the tumors, is the noninvasive papillary neoplasm which progresses to a less differentiated invasive 
transitional cell carcinoma (TCC). Considerable effort has been directed at identifying which of the 
superficial well differentiated papillary tumors will persist, recur and progress to invasive cancer 
Current approaches to identifying such tumors include cytogenetics, molecular biology, and flow 
cytometric DNA analysis. In the final group of bladder carcinomas, the high grade invasive 
neoplasms, evidence suggests that these life-threatening tumors arise de novo without identifiable 
precursors. Unfortunately, 75% to 90% of invasive TCCs are classified in this group, with the 
remaining minority progressing from preexisting recurrent superficial papillary carcinomas. 
Obviously the biologic behavior ofthese aggressive poorly differentiated tumors is life-threatening, 
and application of traditional diagnostic procedures and new technologies need to be directed at early 
diagnosis. (Henry Ford Hosp MedJ 1989:37:19-23) 
Transitional cell carcinoma (TCC) of the urinary bladder is a relatively common neoplasm. The American Cancer Soci-
ety estimates that 45,400 new cases of TCC will be diagnosed in 
1989, accounting for 4.71% of new cancers and approximately 
10,000 deaths. Death from TCC is invariably due to metastases 
which are a direct sequelae of invasion into the bladder wall. 
Large size and deep invasion correlate with the presence of met-
astatic disease. Unfortunately, the vast majority (75% to 90%) 
of invasive TCCs develop de novo without a recognized precur-
sor and only 10% to 25% are preceded by papillary noninvasive 
TCC. The biologic progression of precursors and noninvasive 
TCC is complex and not completely understood. Two separate 
and distinct problems in diagnosing urothelial cancer involve 1) 
early diagnosis of invasive high grade neoplasms, and 2) identi-
fication of predictors of recurrence/progression in patients with 
noninvasive papillary TCC. Exfoliative urine cytology and 
cystoscopy-directed biopsy with direct visualization of the af-
fected urothelium remain the standards for diagnosis and classi-
fication of TCC. 
At initial diagnosis approximately 75% of TCCs are nonin-
vasive tumors (Ta), although some will have microinvasion into 
the lamina propria (Tl). These neoplasms are regarded as super-
ficial tumors and, although symptomatic, are generally not con-
sidered life-threatening. Most noninvasive papillary TCCs are 
well differentiated grade 1 neoplasms with histologic (and 
cytologic) appearances similar to hyperplastic urothelium. Un-
fortunately, approximately two-thirds of these patients will de-
velop recurrent tumors, and 10% to 20% of these recurrences 
will have a less differentiated histologic grade and/or invade into 
the lamina propria or muscle layers of the bladder. Parameters 
associated with recurrence and/or progression include 1) multi-
focal tumors, 2) coexisting severe dysplasia/carcinoma in situ 
(CIS), 3) loss of differentiation antigens such as blood group re-
lated antigens (BGRA), 4) development of marker chro-
mosomes or abnormal cellular DNA content measured by flow 
cytometry or image analysis systems, and 5) histologic 
(cytologic) dedifferentiation to a higher grade. The last three 
factors are closely related as loss of expression of differentiation 
antigens is associated with development of marker chromosome 
abnormalities and deviation from normal (diploid) DNA con-
Submitted for publication: January 10. 1989. 
Accepted for publication: March 16. 1989. 
•Department of ftthology. Henry Ford Hospital. 
tDepartment of Genetics. Henry Ford Hospital. 
TDepartment of Molecular Biology, Henry Ford Hospital. 
§Department of Urology. Henry Ford Hospital. 
Address correspondence to Dr Crissman. Department of Pithology, Henry Ford Hospi-
tal, 2799 W Grand Blvd, Detfoit. Ml 48202. 
Henry Ford Hosp Med J—Vol 37. No 1. 1989 Hormonal Management of Prostate Carcinoma—Miles 19 
tent. These genetic changes usually result in morphologic loss 
of differentiation. We present the current status of diagnostic 
procedures and techniques available for classification of TCC, 
as well as our experience at Henry Ford Hospital in the applica-
tion of new technologies that are being studied in numerous 
institutions. 
Pathology 
The surgical pathology of urothelial neoplasia can be divided 
into three major groups. The most common is the papillary 
(noninvasive) urothelial tumor which represents approximately 
75% of TCC diagnosed. These neoplasms consist of a prolifera-
tion of urothelium which is cytologically similar in appearance 
to normal or hyperplastic urothelium and are well differentiated/ 
grade I TCC. The propensity to proliferate (but not invade) leads 
to an exophytic growth above the adjacent mucosa into the blad-
der lumen, resulting in the characteristic appearance at 
cystoscopy. The exophytic and orderly growth of differentiated 
papillary urothelial neoplasms is a central fibrovascular core 
providing blood supply and mechanical support of the expand-
ing neoplastic urothelium. The well differentiated nature (grade 
I) of the majority of papillary urothelial neoplasms is reflected 
by the difficulties in cytologic diagnosis. Exfoliated cells from 
grade 1 papillary neoplasms are morphologically similar to cells 
shed from nonneoplastic inflammatory/reactive or normal 
urothelium. Urinary tract instrumentation or nephrolithiasis/ 
urolithiasis may also result in exfoliation of cells, resulting in a 
cytologic picture indistinguishable from grade I TCC. The diag-
nosis of well differentiated papillary tumors requires cystoscopy 
with biopsy confirmation. Many patients will have numerous re-
currences of papillary urothelial neoplasms, either in the same 
site (persistence) or at other sites of the urothelium (recurrence). 
Some evidence indicates that patients with severe dysplasia or 
CIS in the adjacent, normal-appearing urothelium are more 
likely to have recurrent neoplasms (1-3). The National Bladder 
Cancer Collaborative Group concluded that coexisting severe 
dysplasia/CIS at sites removed from the papillary tumor are at 
even higher risk for progression to invasive cancer (3,4). A sec-
ond group of patients likely to develop invasive carcinoma are 
those who have recurrent papillary neoplasms with a less differ-
entiated histologic grade (5). Although the frequency of pro-
gression to invasive cancer in patients with dysplasia/CIS is not 
accurately defined, it is unquestionably substantial. In one se-
ries, 42% of patients with differentiated papillary tumors and 
coexisting CIS developed invasive cancer over a 42-month 
period (6). 
Invasive TCC represents the stage of disease responsible for 
tumor-related deaths. Generally invasive TCCs are poorly dif-
ferentiated, high grade (III) neoplasms (5). Curiously, early 
focal or microscopic invasion into the submucosa or lamina pro-
pria (stage A) is not considered life-threatening because these 
tumors are not associated with significant frequency of regional 
or distant metastases and are often grouped with other "super-
ficial" forms of TCC. However, one series found that 30% of 
stage A (microinvasive) TCC progressed to muscle invasion 
over an average follow-up j>eriod of 39 months (7). This obser-
vation supports the ominous nature of any form of tumor inva-
sion. Nevertheless, most invasive urothelial TCCs are not asso-
ciated with or preceded by papillary TCC (8). In a series of 104 
patients with invasive TCC, only 20 had histories of preceding 
papillary (noninvasive) tumors (8). This infrequent progression 
of papillary tumors has been observed by others (5), and thus it is 
generally accepted that the majority of invasive TCCs appear de 
novo, without a preceding diagnosis of urothelial pathology. 
Cytology 
Urinary cytology is a valuable diagnostic tool in the detection 
and follow-up of patients with urothelial neoplasms. Cytology is 
diagnostic of high grade neoplasias, either in situ, papillary, or 
invasive. Cytologic evaluation can be made from a variety of 
specimens including voided urine or urine collected by instru-
mentation, such as catheterization or cystoscopy and bladder/ 
urethral/ureteral washings or brushings. The diagnostic yield 
and accuracy depend on the method of specimen collection, 
cytopreparatory technique, histologic grade of the neoplasm, 
and the skill of the cytopathologist. 
In a hypertonic environment such as urine, exfoliated cells 
rapidly degenerate. Hence, a 24-hour specimen or a first mom-
ing sample is suboptimal for cytologic evaluation. This is also 
necessary for urine from a catheter collection bag or for voided 
urine that contains residual urine in patients with obstructive 
uropathy. A voided urine sample must be submitted fresh to the 
laboratory and processed immediately. If delay is anticipated, 
the urine specimen may be fixed in an equal amount of 50% 
ethyl alcohol and refrigerated. The best method can be chosen 
with consultation of the cytopathologist. The advantage of the 
voided specimen is that it can be easily collected and repeated 
without any invasive techniques. 
Instrumentation can dislodge large numbers of benign epi-
thelial cells, both isolated and in tissue fragments. The latter 
may also be seen in the presence of urolithiasis. In a fluid en-
vironment these tissue fragments of benign epithelium can as-
sume a papillary configuration and are extremely difficult to dif-
ferentiate from epithelial tissue fragments exfoliated from low 
grade well differentiated urothelial neoplasms. A history of in-
strumentation or urolithiasis represents situations where false-
positive diagnosis of well differentiated (grade I) TCC can oc-
cur Indeed, the presence of benign-appearing tissue fragments 
of transitional epithelium in a voided urine sample is abnormal 
and indicative of grade I carcinoma, particularly in a patient 
with no history of recent instrumentation or lithiasis. It is critical 
that such a history be reported to the cytopathologists in order to 
avoid a false-positive diagnosis. 
Diagnostic yield and accuracy depend greatly on the histo-
logic grade of the tumor. With adequate sample, almost all high 
grade TCCs (in situ, invasive, or rarely papillary) can be identi-
fied from cytologic evaluation since malignant cells exfoliating 
from these lesions present with definite, recognizable criteria. 
Grade I (noninvasive) TCCs lack most of the morphologic 
features of malignancy. They spontaneously exfoliate fewer 
cells because of their intercellular attachments associated with 
differentiation. In cytologic presentation, these neoplasms show 
tight cell clusters, rather than single cells, as the tips of the 
papillary fronds break off easily. The frequency of finding these 
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papillary tissue fragments depends on the size of the neoplasm 
and to some extent on the tumor's location. The cytomorphology 
of these cells resembles normal urothelium so closely that their 
cytologic detection is reportedly low, ranging from zero (9) to 
33% (10). The cells of grade I TCC present subtle cellular and 
nuclear abnormalities such as mildly increased nuclear size, in-
creased chromatin content with granularity, and irregularity of 
the nuclear membrane and nucleoli. By considering such fea-
tures. Murphy et al (11) reported 70% diagnostic accuracy for 
grade 1 carcinomas. Grade II TCCs form a spectrum in-between 
grade I and grade III . The exfoliated cells usually show suffi-
cient cellular atypia to be detected in urinary samples. The re-
ported diagnostic accuracy of cytology in grades II and III neo-
plasms varies greatly, with reports ranging from 51% (9), to 73% 
(10), and 94% (11) of patients diagnosed. 
Urinary cytology, especially bladder washing, is a reliable di-
agnostic test in identifying CIS. These intraepithelial car-
cinomas may be difficult to visualize by cytoscopy and often re-
quire random biopsies for diagnosis. The malignant cells from 
CIS or invasive TCC are generally high grade and readily detect-
able by cytology. CIS exfoliates large numbers of single cells, 
allowing their identification in virtually 100% of cases. How-
ever, the presence of high grade malignant cells does not indicate 
the presence or absence of invasion, and the differentiation of 
CIS and invasive carcinoma requires cystoscopy examination. 
Urinary cytology is useful in monitoring patients with a his-
tory of TCC, particularly those cases which progress to less dif-
ferentiated neoplasms. Bladder wash specimens sample a large 
proportion of the bladder mucosa and have the potential to iden-
fify nonvisualized foci of CIS. 
Urothelial Surface Antigens 
Epithelial cells express differentiation antigens on their mem-
brane surface, including the blood group related ABO(H) and 
histocompatibility antigens. The expression of these antigens 
reflects a complicated biochemical pathway beginning with the 
gene(s) coding for the antigen, gene transcription, and protein 
synthesis and transport through the cytoplasm to the membrane 
surface. With some tumors progressing from papillary (nonin-
vasive) to invasive TCC, a loss of BGRA occurs. This loss most 
likely reflects genetic alterations with either loss of the specific 
loci coding for BGRA or a defect in the transcription, synthesis, 
or transport phase. 
Bergman and Javadpour (12) and Lange et al (13) demon-
strated that ABO(H) antigen deletion correlated with advanced 
grade and stage of disease. Unfortunately, ABO(H) antigens are 
extremely sensitive to glycolipid extracting solvents, and the de-
tection of these antigens is optimum only on fresh or frozen cells 
(14). Application of ABO(H) detection loses sensitivity when 
applied to formalin-fixed, paraffin-embedded biopsies of 
urothelial neoplasms (15). 
Acquisition or expression of T antigen (Thomsen-
Friedenreich) (16) appears to represent another surface antigen 
with prognostic value. T antigen is related to the M and N group 
on nonnal erythrocytes and can be unmasked by removal of ter-
minal sialic acid residues with neuraminidase. The presence of 
T antigen is abnormal and is expressed primarily in high grade 
TCC. The greatest value of T antigen detection is in combination 
with ABO(H) expression in patients with superficial, low grade 
TCC. Deletion of the ABO(H) group and expression of T anti-
gen predicts progression and tumor invasion with greater ac-
curacy than ABO(H) deletion alone (17). The detection o fT 
antigen also is best when performed on fresh or optimum-fixed 
cells or on tissue biopsy and is unreliable in formalin-fixed, par-
affin-embedded biopsies. 
DNA Content and Distribution 
Evaluating urothelial neoplasms for DNA content is also 
helpful in the diagnosis and characterization of bladder tumors. 
The optimum technique for measurement of DNA in tumor cells 
is by staining with DNA dyes, such as propidium iodide, and 
quantitating the DNA content of individual cells using flow 
cytometric analysis. This new technology requires single cell 
suspensions which complicates analysis of solid tumors but is 
easily adapted for examination of urine, especially bladder 
washes containing large numbers of single cells. The instrument 
uses an exciting light (laser) which results in excitation of the 
DNA dye (or fluoresceinated antibody, etc) with the emission of 
a light of specific wave length. The emitted light for each event 
(cell) is measured by photosensitive light tubes and analyzed by 
computer. In this manner, the instrument is capable of analyzing 
hundreds of cells per second. 
DNA analysis by flow cytometry is capable of measuring two 
major parameters: the total DNA content of the tumor cell popu-
lation, and the fraction of cells synthesizing DNA (specific-
pathogen free [SPE]). The former is calculated relative to ex-
pected DNA content of normal (diploid) cells that contain 46 
chromosomes and is expressed as the DNA index. For instance, 
a DNA index of 1 is normal; less than or greater than 1 reflects 
loss or increase of chromosomal material and is abnormal 
(aneuploid). The SPF is expressed as a fraction of the tumor cell 
population which is synthesizing DNA; the greater this percent-
age, the more cells that are actively synthesizing DNA and pre-
sumably actively proliferating. 
Flow cytometry is a technologic advance that can quan-
titatively measure subcellular changes not evident with the light 
microscope. Using propidium iodide, which differentially 
stains DNA, cellular changes in DNA content (ploidy) can 
be quantitatively measured in single cell suspensions (18). In 
our study of 75 bladder washings comparing flow cytometric 
DNA analysis of ethanol-fixed cells with cytospin prepared 
Papanicolaou (standard) cytologic analysis, 45% of the samples 
examined had normal cytology but contained abnormal DNA 
(hyperdiploid and tetraploid) (19). Abnormal DNA content is an 
indicator for the aggressive potential of bladder tumor cells 
since it is associated with higher histologic grades II and III and 
a higher frequency of progression to invasion (20,21) (Table 1). 
Thus, flow cytometry is useful in monitoring patients with 
known bladder carcinomas and may predict the papillary tumors 
likely to progress to invasive TCC if sufficient chromosomal 
abnormalities exist. 
Cytogenetics 
Cytogenetic markers are established parameters for the diag-
nosis and management of patients with hematologic disorders. 
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Table 1 
Urothelial Neoplasia: Henry Ford Hospital Experience* 
Grade 
Histologic Grade I n III 
Noninvasive (Ta) 4 7 0 
Submucosal invasion (Tl) 0 2 1 
Muscle invasion (T2 -t-) 0 0 12 
Diploid range DNA 4 8 2 
Aneuploid DNA () 1 11 
Total 4 9 13 
*From Crissman JD, Liu BS, Zarbo RJ, et al. Diagnosis of urothelial neoplasia. Cytome-
try 1988;2(suppl):8. 
Table 2 
Relation of Blood Group Related Antigen, H-Ras Product 
(p21), and DNA Studies: Henry Ford Hospital Experience* 
Tumor Cells Positive ABH (%) T (%) p2I (%) 
Diploid range DNA (14) 50.0 19.8 56.0 
Normal cytogenetics (4) 29.4 17.4 67.0 
Abnormal cytogenetics (9) 40.0 20.6 49.0 
Aneuploid DNA (12) 27.9 14.6 40.3 
Cystitis (8) 33.6 13.4 16.6 
*From Crissman JD, Liu BS. Zarbo RJ. et £ 
try I988;2(suppl):8. 
Diagnosis of urothelial neoplasia. Cytome-
Several characteristic markers have been identified in lympho-
mas and leukemias, such as the translocation (15,17)—a spe-
cific rearrangement for acute promyelocytic leukemia. This 
chromosome change has not been described in any other form of 
cancer. 'Virtually all subgroups of acute nonlymphocytic leuke-
mias have been further classified based on the presence of spe-
cific chromosome markers. The application of cytogenetic 
marker studies in hematopoietic neoplasms has progressed; co-
operative cancer study groups are developing protocols for 
clinical trials stratified by cytogenetic study. Technical limita-
tions have hampered progress in the cytogenetics of solid tu-
mors. Improvements in tissue culture including tumor disag-
gregation by enzyme digestion, application of enriched media, 
and synchronization of cells in culture have contributed to ad-
vances in cytogenetic studies of solid tumors including TCC. 
The value of chromosome analysis as a prognostic factor in 
patients with TCC was recognized as eariy as 1971 by Falor and 
Ward. Marker chromosomes predicted for tumor recurrence in a 
later follow-up study by the same investigators (22). Trisomy 7 
and monosomy 9 have been established as primary markers in 
bladder cancer because these two changes were observed as sole 
abnormalities in some tumors (23). Establishing primary and 
secondary chromosome abnormalities for any tumor type is 
important because they may be involved in initiation and/or pro-
gression of the tumor. We identified several nonrandom changes 
in TCC: deletion of short arm (p) of chromosome 11, duplication 
of 3p, deletion of long arm (q) of 6, trisomy 7, and duplication of 
lq (24). Trisomy 7 is a good candidate for a primary genetic 
event, whereas others are most likely secondary changes. In ad-
dition, tumors with l ip deletion and 3p duplication were associ-
ated with a higher likelihood of tumor progression. We continue 
to perform cytogenetic analysis on all bladder tumors in an at-
tempt to better define chromosomal abnormalities of prognostic 
value (Table 2). 
Oncogenes as Himor Markers 
Oncogenes are genes that cause or are associated with cancer. 
They represent altered versions of a group of normal genes 
(proto-oncogenes) that exist in every cell. When these proto-
oncogenes are changed by point mutations or by translocation 
from their usual position on one chromosome to another or have 
their transcription-initiation sites altered, they may produce a 
protein with a different configuration, an excess of their protein 
product, or may express this product at an inappropriate time of 
the cell cycle. These changes have been shown to confer trans-
forming properties leading to neoplasia, and therefore these al-
tered genes are referred to as oncogenes (25-27). 
DNA from certain naturally occurring human tumors can in-
duce malignant transformation in the NIH-3T3 fibroblast cell 
line. The first oncogene identified in a human tumor was the ras 
oncogene, which was isolated from a human bladder cancer cell 
line. Examination of the ras gene identified in the bladder can-
cer cell line indicates that a point mutation at codon 12 is respon-
sible for its transforming capabilities. This mutation has been 
found in some other human cancers including lung and colon 
carcinomas. Slamon et al (28) demonstrated cellular oncogene 
activity in tissues obtained from fresh human tumors. They 
studied tumors from 54 patients representing 20 different cell 
types and tested for the presence of 15 different oncogenes. The 
ras oncogene, as well as myc and fos oncogenes, were expressed 
in nearly all of the tumors studied. Other oncogenes were ex-
pressed infrequently, and some were not detected. Recent stud-
ies using restriction fragment length polymorphism (RFLP) of 
the human C-Ha-ras-1 gene indicated the association of variable 
tandem repeat sequences in some cancer patients with the pos-
session of a rare Ha-ras allele (29,30). A similar association be-
tween rare alleles of C-mos and certain human cancers has also 
been reported (31,32), providing further evidence for the 
usefulness of RFLPs at proto-oncogene loci in determining pre-
disposition of certain cancers including urothelial neoplasia. 
The ras oncogene produces an immunogenic protein (p21) 
that can be used to generate antibodies which can recognize this 
oncogene product. The nature of bladder cancer invites applica-
tion of monoclonal antibody techniques for early diagnosis and 
monitoring of disease since it is readily sampled. We have iden-
tified that p21 expression is a better monitor of neoplastic cell 
populations than BGRA deletions or expression of T antigen 
(33) (Table 2). Urothelial carcinomas arise in the superficial lin-
ing of the urinary tract, and these neoplastic cells are bathed 
constantly in urine and exfoliate readily. Cellular metabolites of 
the cancer may also be presumed to be secreted or shed into the 
urine. Using antisera generated against the ras oncogene prod-
uct, we have identified ras oncoproteins in urine of patients with 
TCC. Using an immunologic assay (enzyme-linked immuno-
sorbent assay), we have demonstrated the presence of ras 
expression in urine in 70% of patients with bladder cancer. Fur-
thermore, increased level of ras expression was associated with 
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higher tumor grade and increasing stage. We also detected the 
ras oncogene product within the cytoplasm of exfoliated tumor 
cells in patients with elevated ras oncoprotein expression in their 
urine. 
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